Kornimate/medical-research-clean huggingface dataset:
familial hypocalciuric hypercalcemia: clinical aspects and evolution

Conditions: Familial Hypocalciuric Hypercalcemia

Summary: familial hypocalciuric hypercalcemia (fhh) is a rare disease (orpha#405, www.orpha.net) and most likely underdiagnosed, that clinicians should be aware of in the differential diagnosis of a hypercalcemia. appropriate identification of the fhh has implications in treatment and also for the family, since it is an automosal-dominant disease, due to mostly a heterozygous loss-of-function mutation of the casr (calcium-sensing receptor) gene, but also much less freqüent mutations of another two genes (ap2s1 and gna11). in case of clinical and biochemical suspicion of fhh, a genetic evaluation is mandatory. nevertheless, an important number of patients, the genetic study is negative. this observational study is intended to perform a descriptive review of cases with clinical and biochemical suspicion of fhh who underwent a genetic study in the usual clinical practice. clinical, biochemical and radiological characteristics, treatment, follow-up and comorbidities of genotype-negative participants will be compared with genotype-positive cases.


Eligibility criteria:
inclusion criteria: * patients with clinical and biochemical suspicion of fhh who, at the discretion of the physician in routine clinical practice, were asked to perform a genetic evaluation of fhh and whose genetic results are available. exclusion criteria: * genetic study of fhh is not available or was not performed despite clinical and biochemical suspicion of fhh.

Keywords: hypercalcemia familial benign hypercalcemia familial hypocalciuric hypercalcemia
safety and efficacy study of pegylated interferon lambda versus pegylated interferon alfa, plus ribavirin in subjects with hepatitis c

Conditions: Hepatitis C Virus (HCV)

Summary: the purpose of this study is to determine if 48 weeks of therapy with pegylated interferon lambda plus ribavirin is effective and safe for a treatment of chronic hepatitis c (chc) compared to therapy with pegylated interferon alfa-2a plus ribavirin.


Eligibility criteria:
inclusion criteria: * chronic hepatitis c, genotype 1 or 4 * hcv ribonucleic acid (rna) ≥ 100,000 iu/ml at screening * liver biopsy documenting no cirrhosis (within prior 2 years) or cirrhosis (from any time prior to randomization). where approved for staging of liver disease, non-invasive imaging may be used to assess the extent of liver disease. subjects with compensated cirrhosis can enroll and will be capped at 10% * naive to prior anti-hcv therapy exclusion criteria: * infected with hcv other than genotype 1 or 4 * positive hepatitis b surface antigen (hbsag), or human immunodeficiency virus-1 (hiv-1)/hiv-2 antibody or hepatitis d virus (hdv) at screening * evidence of liver disease other than hcv * active substance abuse * use of hematologic growth factors within 90 days prior to study randomization * evidence of decompensated cirrhosis based on radiologic criteria or biopsy results and clinical criteria
efficacy & safety of clindamycin and tretinoin in acne

Conditions: Acne

Summary: the purpose of this study is ascertain the efficacy and safety of clindamycin phosphate 1.2% and tretinoin 0.025% in the treatment of acne and post inflammatory hyperpigmentation in patients with skin of color.

acne is a chronic disorder of the pilosebaceous glands characterized by inflammatory papules, pustules, opened and closed comedones, cysts and nodules. post inflammatory hyperpigmentation is a condition in which an inflammation from a disease such as acne, trauma, or abrasion results in areas of the skin with increased melanin content compared to the surrounding skin. there are several treatments available for acne, which include benzoyl peroxide,antibiotics (topical or oral), and topical retinoids (tretinoin, tazarotene, adapalene). combination therapy, such as topical retinoid and clindamycin, has been shown to be more effective than monotherapy in addressing all pathogenic factors of acne.

Eligibility criteria:
inclusion criteria: * mild to moderate facial acne and mild to moderate post-inflammatory hyperpigmentation * photo skin types iv - vi * ages 12 and older * both sexes * two week washout period for topical anti-acne medications, medicated cosmetics,and bleaching products * thirty day washout period for oral corticosteroids, oral antibiotics,and oral contraceptives exclusion criteria: * seborrheic dermatitis * pih of solely dermal origin * acne vulfaris known to be resistant to oral antibiotics * use of erythromycin-containing products * use of neuromuscular blocking agents * pregnancy, breastfeeding, a positive pregnancy test in the office, or plans to become pregnant. women of childbearing age must use reliable forms of contraception (e.g., abstinence, oral contraceptives, or spermicide and condoms).

Keywords: hyperpigmentation
effects of glutamine on glp-1 and insulin secretion in man

Conditions: Type 2 Diabetes

Summary: this study investigated the effect of glutamine, an amino acid, glycemia, glucagon-like peptide-1 (glp-1) and insulin in participants with type 2 diabetes.

in this study, we investigated the effect of glutamine, an amino acid, on glycemia and on glp-1 and insulin in participants with type 2 diabetes. preliminary data published by our group suggests that glutamine is a strong determinant of glp-1 secretion in vitro. we tested the hypothesis that glutamine lowers postprandial blood glucose and investigated whether the dipeptidyl peptidase-4 (dpp-4) inhibitor sitagliptin modifies this effect.

Eligibility criteria:
inclusion criteria: * type 2 diabetes, on metformin or diet alone (not sulphonylureas or insulin) exclusion criteria: * malabsorption, renal or liver disease, treatment with steroids
evaluation of the safety, tolerability, and efficacy of mdgn-002 in adults with moderate to severe active crohn's disease or ulcerative colitis

Conditions: Crohn Disease; Ulcerative Colitis

Summary: this is a phase 1b, open-label, dose-escalation, signal-finding, multi-center study. the study will evaluate the safety, tolerability, pharmacokinetics and short-term efficacy of mdgn-002 in adults with moderate to severe, active crohn's disease or ulcerative colitis who have previously failed anti-tumor necrosis factor alpha (anti-tnfα) treatment.


Eligibility criteria:
inclusion criteria: 1. subject is male or female, ≥ 18 to ≤ 75 years of age. 2. subject has a documented diagnosis of cd via endoscopy/colonoscopy and histological confirmation, or subject has received a diagnosis of uc for 90 days or greater prior to visit 1, confirmed by endoscopy during the screening period, with exclusion of current infection, dysplasia and/or malignancy. 3. subject has moderate to severe, active cd as evidenced simple endoscopy score for crohn's disease (ses-cd) score of ≥7, and histological confirmation, or subject has moderately to severely active uc, as defined by a modified mayo score (excluding the pga component) of 5 to 9 points at visit 1. 4. subject has failed treatment with an approved therapeutic dose of an anti-tnfα monoclonal antibody treatment. exclusion criteria: 1. subject has a diagnosis of ulcerative colitis (uc) or indeterminate colitis or subject has a diagnosis of crohn's disease or indeterminate colitis . 2. subject with signs or symptoms of bowel obstruction. 3. subject has short bowel syndrome. 4. subject has a current functional colostomy or ileostomy. 5. subject has had a surgical bowel resection within the past 6 months prior to screening or is planning any resection during the study period. 6. subject is pregnant or a nursing mother. 7. subject is sexually active and not using effective contraception as defined in the protocol.
targeting the carotid bodies to reduce disease risk along the diabetes continuum

Conditions: Type 2 Diabetes

Summary: our overall goal is to advance our understanding of the contribution of the carotid body chemoreceptors in glucose regulation and the development of type 2 diabetes.


Eligibility criteria:
inclusion criteria: * healthy, * type 2 diabetes * bmi 18-40 kg/m2, * non-pregnant, * non-breastfeeding, * non-nicotine users. exclusion criteria: * cardiovascular disease including myocardial infarction, heart failure, coronary artery disease, stroke; * renal or hepatic diseases; * active cancer; * autoimmune diseases; * immunosuppressant therapy; * excessive alcohol consumption (\>14 drinks/week); * current nicotine use; * foot ulcers; * diabetic neuropathy; * medication directly influencing sympathetic nervous system activity
establishing video decision aids for geriatric patients with frailty to promote advance care planning

Conditions: Frailty

Summary: the goal of this observational study aimed to develop and assess a video decision aid for advance care planning in geriatric patients with frailty. the main question it aims to answer is: the video decision aid comprehensibility, usability, feasibility? the video includes an introduction to geriatric frailty (3 minutes) and advance care planning (5 minutes). advance care planning includes three levels of medical care: life-prolonging care, limited care, and comfort care.


Eligibility criteria:
inclusion criteria: * phase 1 - patients 1. aged 65 or older. 2. have not completed an advance directive (ad) document. 3. able to communicate in mandarin or taiwanese. 4. have adequate vision and hearing to watch a video in mandarin or taiwanese on a tablet. 5. willing to participate in the study after explanation. * phase 1 - family members 1. aged 18 or older. 2. have not completed an advance directive (ad) document. 3. able to communicate in mandarin or taiwanese. 4. have adequate vision and hearing to watch a video in mandarin or taiwanese on a tablet. 5. willing to participate in the study after explanation. * phase 1 - healthcare providers 1. have not completed an advance directive (ad) document. 2. able to communicate in mandarin or taiwanese. 3. willing to participate in the study after explanation. * phase 2 - patients 1. aged 65 or older. 2. have participated in shared decision-making (sdm) using decision aid tools. 3. have experience in advance care planning (acp) consultation or have completed related written advance directive documents. 4. able to communicate in mandarin or taiwanese. 5. have adequate vision and hearing to watch a video in mandarin or taiwanese on a tablet. 6. willing to participate in the study after explanation. * phase 2 - healthcare providers 1. have professional knowledge and practical experience in advance care planning (acp). 2. have experience caring for frail elderly populations. 3. able to communicate in mandarin or taiwanese. 4. willing to participate in the study after explanation. exclusion criteria: 1.cognitive impairment, unable to communicate clearly.

Keywords: frailty advance care planning video decision aids
adolescent controlled text messaging to improve asthma medication adherence in primary care

Conditions: Persistent Asthma

Summary: a randomized controlled trial of a texting intervention to increase adherence to preventative asthma medication in four cincinnati children's hospital medical center primary care clinics.

our first aim is to determine the feasibility, acceptability and use of a low intensity text messaging intervention to improve adherence to inhaled corticosteroid (ics) therapy among high risk adolescents with persistent asthma. our second aim is to determine effect sizes of the intervention to improve adherence (as measured by electronic monitoring and self-report); clinical asthma control; and asthma related quality of life among adolescents with persistent asthma. our third and final aim is to determine the temporal relationship between text message receipt and ics canister actuation in order to understand mechanisms by which text messaging may increase ics adherence.

Eligibility criteria:
inclusion criteria: * provider-diagnosed persistent asthma * prescription of an ics in accordance in nhlbi expert panel report 3 guidelines for at least 30 days prior to enrollment * asthma control test (act) score less than 20 (indicating lack of current control) * no provider-diagnosed exacerbation in the 30 days prior to enrollment * possession of a text-enabled cell phone and a plan to keep it throughout the study period * agreement by parents (or participants over 18 years old) to any charges levied by their cell phone carrier for text messages associated with the study if they do not have an unlimited texting plan * speak and read english exclusion criteria: * another chronic lung disease (which would complicate measurement of asthma control) * cognitive or psychiatric disorder that the treating clinician judges would impair study participation * use of advair diskus for their ics (for which no reliable electronic monitor exists) * current enrollment in another asthma intervention study

Keywords: persistent asthma adherence text message reminders
camrelizumab and apatinib for neoadjuvant therapy in thyroid cancer

Conditions: Thyroid Cancer

Summary: to determine the efficacy and safety of anti-pd-1 antibody camrelizumab combined with apatinib for neoadjuvant therapy in locally advanced thyroid cancer.


Eligibility criteria:
inclusion criteria: * the patient volunteered to participate in the study and signed an informed consent form; * pathologically diagnosed locally advanced thyroid cancer, including papillary thyroid cancer, medullary cancer, follicular cancer, poorly differentiated cancer, etc., require surgical resection with or without distant metastasis; * preoperative assessment of locally advanced thyroid cancer (unable to achieve r0/1 resection or t4 disease); * have at least one measurable lesion (recist 1.1); * age\>=14 years, eastern cooperative oncology group (ecog) score 0-1; * patient agree to receive surgery/ core needle biopsy before and after neoadjuvant treatment. * the main organ functions meet the criteria before treatment. exclusion criteria: * patients who have previously been treated with immune checkpoint inhibitors (including but not limited to nivolizumab, pembrolizumab, teriplizumab, sintilizumab, etc.); * received external radiation therapy or iodine-131 therapy within the past 28 days; or planned systemic anti-tumor therapy during this study; * pathologically confirmed non-thyroid epithelial cell-derived malignant tumors (including lymphoma, metastatic cancer, sarcoma, etc.); * with other uncontrolled / under treatment malignancies; * those who have multiple factors (such as inability to swallow) that affect oral medication; * patients with any severe and / or uncontrolled illness, * patients whose imaging showed that the tumor had invaded the important blood vessels or the researchers judged that the tumor was likely to invade important blood vessels during the subsequent study period and caused fatal bleeding; * according to the investigator's judgment, there are concomitant diseases that seriously endanger the safety of patients or affect patients to complete the research.

Keywords: thyroid cancer locally advanced neoadjuvant camrelizumab apatinib
baseline epidemiologic assessment of abuse-deterrence of morphabond extended release (bead-mb)

Conditions: Baseline Epidemiologic Assessment

Summary: the main objectives of this study are to provide surveillance/descriptive data to (a) assess utilization of morphabond er and selected comparators overall and by age group and census regions using nationally-projected quarterly drug dispensing data and (b) assess the scope and pattern of abuse and clinical outcomes for morphabond er using nationally representative data or data from large geographic areas in different populations. findings of this study will support the design of formal epidemiology assessment of the risks of addiction, overdose, and death outcomes associated with morphabond er and appropriate comparators in the future.

the study started after the launch of morphabond er in october 2017 and will continue until september 2020 and the final study report will be submitted to the fda by december 2020. this is an observational study that will provide descriptive data on the utilization and abuse of morphabond er and related outcomes (addiction, misuse, abuse, overdose, overdose-related deaths) for morphabond er and selected comparators in response to the us-fda's post-marketing requirement (pmr 2961-9 for morphabond er). no investigational products or pharmaceutical agents will be provided or administered for the purpose of this study. multiple data sources, representing different populations and large geographic areas in the us, will be utilized to study the patterns of morphabond er utilization and abuse and related outcomes. the overall purpose of this study is to collect meaningful baseline data to support subsequent studies for formal epidemiologic assessment of abuse deterrence of morphabond er as required by the fda.

Eligibility criteria:
inclusion criteria: * male or female * morphabond er users or relevant comparator users exclusion criteria: * not applicable

Keywords: abuse misuse overdose
kidnet versus meditation/relaxation - a dissemination rctt for children in sri lanka traumatized by the war and the tsunami

Conditions: Post-Traumatic Stress Disorder

Summary: the purpose of this study is to assess the efficacy of kidnet versus a meditation/relaxation protocol in treating traumatized children in sri lanka when applied by locally trained teacher counsellors.


Eligibility criteria:
inclusion criteria: * children with preliminary ptsd diagnosis (except for time criterion) in the age range of 8 to 14 years living in a specific idp camp after the tsunami disaster. exclusion criteria: * mental retardation, psychosis, any neurological disorder

Keywords: post-traumatic stress disorder (ptsd)
pancreatic cancer detection consortium (pcdc) prospective cohorts

Conditions: Pancreatic Carcinoma

Summary: this study evaluates individuals without pancreatic cancer, but who have been determined to be at higher-than-average lifetime risk of developing pancreatic cancer to help detect pancreatic cancer or other cancers at an earlier time when they might be more easily treated and cured.

primary objectives: i. to develop a cohort (biobank of biospecimens and data) of subjects without pancreatic cancer who are at highrisk for pancreatic cancer due to: a strong family history, a mutation in a known pancreatic cancer predisposition gene, or fukuoka worrisome or high-risk pancreatic cysts. ii. to follow the cohort subjects longitudinally and collect biospecimens and follow-up data and record medical outcomes. iii. to make biospecimen available to pcdc-approved projects to validate potential biomarkers for performance using nested case-control prospective designs. outline: this is an observational study. participants undergo blood sample collection, complete questionnaires, have their medical records reviewed and undergo pancreatic cyst fluid collection during standard of care endoscopic ultrasounds fine needle aspiration.

Eligibility criteria:
inclusion criteria: * pdac family history or pdac related genetic mutations: * age: 50 or older, plus at least one of the following: * mutation unknown or absent: * 2+ relatives with pdac on same side of family where 2 affected are first degree related to each other and at least 1 affected is first degree related to subject; * or 2+ affected first degree relatives (fdr), defined as blood related parents, siblings, or children) * known pathogenic/likely pathogenic (p/lp) mutation in at least one of the following: * cdkn2a/p16, pjs (stk11), hereditary pancreatitis with confirmed protease serine 1 (prss1) * or 1+fdr or second degree relative (sdr) with pdac and a known p/lp mutation in one or more of: * atm, brca1, brca2, palb2, lynch syndrome (mlh1, msh2, msh6, pms2, epcam), tp53 high-risk or worrisome pancreatic cysts: * 18 years of age or greater and meeting fukuoka worrisome (fw) or fukuoka high-risk (fhr) criteria * high risk stigmata: * obstructive jaundice in a patient with cystic lesion of the head of the pancreas * enhancing mural nodule ≥ 5 mm * main pancreatic duct ≥ 10 mm * worrisome features: * presence of pancreatic duct stricture, defined as focal pancreatic duct narrowing with upstream duct =\> 6 mm * cyst ≥ 3 cm * enhancing mural nodule \< 5 mm * thickened/enhancing cyst wall * main duct size 5-9 mm * pancreatitis * lymphadenopathy * increased ca 19-9 * cyst growth rate ≥ 5 mm /2 years exclusion criteria: * \* is unable to provide informed consent * has received a non-autologous bone marrow transplant or has an active hematologic malignancy (i.e., leukemia or lymphoma) * current or prior history of pdac or total pancreatectomy * is currently a prison inmate * is not able to speak or read english
study on the relationship between iodine nutrition and thyroid diseases in the elderly

Conditions: Nutrition, Healthy; Elderly

Summary: the aging trend of china's population is intensifying. more than 50% of the elderly in china suffer from thyroid disease. thyroid dysfunction in the elderly increases the risk of cardiovascular and metabolic diseases. even if thyroid-stimulating hormone (tsh) is within the normal range, brain atrophy and infarction-like vascular damage in elderly males will be aggravated with the increased tsh level. iodine is an essential component of thyroid hormones. iodine deficiency or excess may lead to a series of thyroid diseases. the risk threshold of iodine intake in the elderly is unknown. the goal of this observational study is to clarify the relationship between thyroid diseases and iodine intake in the elderly. the aims are: 1. to clarify the differences in the prevalence of thyroid diseases in the elderly with different iodine nutrition backgrounds. 2. to analyze the effects of mild iodine deficiency and iodine excess on the thyroid health of the elderly. 3. to explore the hazard threshold of iodine intake for old people. 4. to compare the differences in thyroid disease and iodine nutritional status between young and middle-aged people and old people.

part 1：a cross-sectional survey of thyroid diseases in adults in different iodine nutrition background areas. investigators will separately include adults ( middle-aged people and old people) in iodine-deficient, iodine-appropriate, and iodine-excessive areas. venous blood will be collected to measure thyroid function and serum iodine. thyroid volume and nodular disease were determined by b-ultrasonography. drinking water, saliva and 24-h and spot urinary samples will be collected to precisely evaluate the daily iodine intake. multiple indicators were used to accurately evaluate the iodine intake level of the subjects, and understand the differences in the prevalence of thyroid diseases in the elderly under different iodine nutrition backgrounds. besides, the differences in thyroid disease and iodine nutritional status between young and middle-aged people and old people will be compared. part 2：a survey on the iodine nutrition status in the elderly with/without thyroid disease in iodine-appropriate areas. investigators will collect basic information (height, weight, age, other medical histories, etc.) and thyroid disease history information. thyroid b-ultrasound and thyroid function tests were used to understand the current thyroid status of the elderly. the iodine dietary frequency questionnaire was used to assess the long-term iodine intake level of the survey subjects, and spot urinary iodine, 24-h urinary iodine and salivary iodine were used to assess the short-term iodine intake level of the survey subjects.

Eligibility criteria:
inclusion criteria: 1. adults with at least 5 years of local residence; exclusion criteria: 1. adults with family genetic diseases 2. adults with special dietary habits 3. adults taking iodine-containing drugs or supplements 4. adults with protein or nutritional deficiencies

Keywords: iodine thyroid diseases adults